Dr. Judit Cubedo

Co-Founder & Chief Executive Officer (CEO)

Dr. Cubedo holds a PhD in Molecular and Cellular Biology from the University of Barcelona and an MBA from La Salle University. She has solid expertise in biomarker discovery, gained from 12 years spent conducting several research lines on clinical differential proteomic studies, biomarker validation studies and the characterization of protein post-translational modifications, for the identification of new biomarkers of cardiovascular risk and its clinical manifestations.

She has published more than 30 scientific publications in high-impact journals, including original papers and reviews, and two book chapters, and she holds four patents. During her last years in academic research her work was addressed to the development of immunobased assays for the detection of novel potential biomarkers of cardiovascular disease with transfer and commercialization potential. She was awarded with the Innovators Under 35-Spain MIT Technology Review award for the development of the first prototype to quantify ApoJ-Glyc as a biomarker of ischemia.

As CEO of GlyCardial, she has leaded  critical stages such as the technology transfer process from the Institution into the Company, the incorporation of GlyCardial Diagnostics and the raising of the first funding round of the company of 2.4M€ with two Venture Capital firms in order to start the development plan of the company. Currently she directs the scientific aspects of the project and oversees its overall implementation, progress, and success.